Navigation Links
Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
Date:3/19/2008

MELBOURNE, Australia, March 19 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has received ethics approval to commence treating patients with Type 1 diabetes in a Phase 2 clinical trial using its patented transdermal insulin delivery system, TPM/Insulin. The lead clinical investigators of the trial will be Dr. Michael D' Emden, Department of Endocrinology, Royal Brisbane and Women's Hospital, and William Hsu, who is an Assistant Investigator in the Section on Clinical Research at the Joslin Diabetes Centre and an Assistant Professor of Medicine at Harvard Medical School, Boston, MA.

Ethics approval was granted on the basis of data generated from previous trials and the first arm of the Phase 2 trial, which involves the treatment of patients with Type 2 diabetes. Phosphagenics had to demonstrate safety and the effective delivery of insulin into the bloodstream of patients with Type 2 diabetes prior to receiving ethics approval to commence a trial for patients with Type 1 diabetes.

The Phase 2 trial in Type 1 patients is due to commence next month and will be conducted at QPharm in Queensland, Australia. QPharm is a well- established clinical facility and uniquely placed to conduct this type of diabetes trial. The trial is a randomized, single-blinded trial which aims to assess the efficacy of TPM/Insulin. The results of this trial will be used to assist in obtaining an IND from the FDA. This will enable Phosphagenics to commence the next phase of its clinical development program for TPM/Insulin at the Joslin Diabetes Centre. It is anticipated that the U.S. portion of the study will start this year.

"We have gathered the appropriate positive data to progress our Phase 2 study to the treatment of patients with Type 1 diabetes, which is the ideal patient population to prove the efficacy of our TPM/Insulin," said Dr. Esra Ogru, Executive Vice President of Research and Development at P
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
2. Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
5. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... Conference Call Scheduled for Tuesday, December 9...n AML -- , , SOUTH SAN FRANCISCO, Calif., ...euticals, Inc. (Nasdaq: SNSS ), a biopharmaceuti...ialization of new oncology therapeutics, today ann...cute myeloid leukemia (AML) will be presented duri...
(Date:12/1/2008)...N DIEGO, Dec. 1 Vical In...eceipt of a $1.0 million milestone payment from Me...ation of a Phase I clinical trial of an investigat...date vaccine is based on Vical,s DNA gene delivery...ranscriptase (hTERT). hTERT is the subject of sepa...
(Date:11/30/2008)...ICAGO, Dec. 1 Abnormali...aluated in children with autism spectrum disorder ...o a study presented today at the annual meeting of... , , "Using MEG, we can record the tiny mag...vity," said Timothy Roberts, Ph.D., vice chair of ...
(Date:11/28/2008)...DIANAPOLIS, Nov. 28 Eli ...s supplemental New Drug Application (sNDA) from,t...balta(R) (duloxetine HCl),for the management of c...on in,the first half of 2009, adding data from a ...oarthritis pain of the knee. , The decision...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Researchers ID New Gene Linked to Lung Cancer 3773 1Researchers ID New Gene Linked to Lung Cancer 3773 2WallSt net Updates Investment Community Through All New Interview With XTend Medical 3771 1WallSt net Updates Investment Community Through All New Interview With XTend Medical 3771 2Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity 3766 1Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity 3766 2Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity 3766 3Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity 3766 4Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 1Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 2Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 3Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 4Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 5
...taneous administration show potential for,new opti... June 04, 2007 /PRNewswire-FirstCall/ -- Millenniu...tation of positive,data for VELCADE, the market-le...MM) who have received at least one prior therapy.,...or subcutaneous,(SC) administration of VELCADE, a ...
...ents With Follicular Lymphoma Reported,Today at AS...Newswire/ -- GlaxoSmithKline plc,announced today l...single one-week course of frontline treatment with...d Iodine I-131 Tositumomab) in,76 patients with ne...mphoma (NHL). This regimen was found to induce dur...
Other Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 78-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:12/1/2008)...esses common, study shows , , MONDAY, D...e common among young adults in the United States, ...o reach this finding, U.S. researchers analyzed da..., who took part in the National Epidemiologic Surv...dy found that 45.8 percent of the 2,188 college st...
(Date:12/1/2008)...goals, commitment and resources , , MO...ticism that it has done a poor job safeguarding th...inistration released a report Monday detailing its... important changes in 2008 was the agency,s initia...local health departments to protect the food suppl...
(Date:12/1/2008)... Institute,s cancer registry has found that as man... incomplete radiation treatment following breast-c...an lead to worse outcomes. , Dr. Heather Taffet ...es found that among a nationally representative sa...ts aged 65 and older, almost 1,300 women experienc...
(Date:12/1/2008)... -- Due to the urgent need to disseminate authorit...h and clinical care, publisher Mary Ann Liebert ...l archival online issues of the company,s AIDS jou...d AIDS Day. Free online access is available for ...apc ) and AIDS Research and Human Retroviruses ...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
...mpany, has acquired Innovation Sports, Inc., a U.S...The acquisition of Innovation Sports comes on the ...Medical in the U.S., and the December 2005 acquisi...ese acquisitions, and its 2003 acquisition of Gene...
...ster of the Indian State of Bihar has been given t...tish Kumar, the State’s Chief Minister is reported...m the city of Patna. Sources close to Nitish Kum...ve the law and order situation in the state, but e...
...e Cancer Center – Arthur G. James Cancer Hospital ...nd a tumor suppressor gene that could be of vital ...ancers as well as lung cancer. //Their study shows...he development of the aforementioned cancers.<...
...staff, it has been proposed to extend the Medicare... currently played by nurses, podiatrist surgeons a...her extended to accomodate them into vacant postit...rom doctors and other health professionals. The pr...
Other Medicine News:Health News:Ossur Acquires the U.S. Orthopaedics Company 2Health News:Unusual Tumor-Suppressor Gene Switches Off in Lung Cancer 2Health News:Additional Responsiblities To Be Taken Up By Allied Healthcare Professionals 2
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade.
Low-profile hand-held instruments.
The BioPro Basal Thumb joint is manufactured from Cobalt Chrome and is used to replace the Trapeziometacarpal joint.
Anatomic implant shape and easy-to use instrumentation promote implant alignment, stability, and restored joint kinematics.
Medicine Products: